Learn About Acute Monoblastic Leukemia (AmoL)

What is the definition of Acute Monoblastic Leukemia (AmoL)?
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
Save information for later
Sign Up
What are the alternative names for Acute Monoblastic Leukemia (AmoL)?
  • Acute monoblastic leukemia
  • AML M5
  • AML-M5
  • Acute monocytic leukemia
  • Acute myeloblastic leukemia type 5
Who are the top Acute Monoblastic Leukemia (AmoL) Local Doctors?
TK
Dr. Tapan M. Kadia
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
32
conditions
Oncology
Hematology Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Tapan Kadia is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Kadia has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Acute Monoblastic Leukemia AmoL. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome MDS, Leukemia, and Acute Myeloblastic Leukemia with Maturation. He is licensed to treat patients in Texas. Dr. Kadia is currently accepting new patients.

View Profile
JS
Jan Stary
Elite
Highly rated in
16
conditions

Charles University And University Hospital Motol

Prague, PR, CZ 

Jan Stary is in Prague, Czech Republic. Stary is rated as an Elite expert by MediFind in the treatment of Acute Monoblastic Leukemia AmoL. They are also highly rated in 16 other conditions, according to our data. Their top areas of expertise are Acute Lymphoblastic Leukemia ALL, Acute Monoblastic Leukemia AmoL, Leukemia, and Juvenile Myelomonocytic Leukemia.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
RW
Dr. Roland B. Walter
Hematology
Elite
Highly rated in
16
conditions
Hematology

Seattle Cancer Care Alliance

1354 Aloha St 
Seattle, WA 98109

Roland Walter is a Hematologist in Seattle, Washington. Dr. Walter has been practicing medicine for over 26 years and is rated as an Elite doctor by MediFind in the treatment of Acute Monoblastic Leukemia AmoL. He is also highly rated in 16 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Acute Myeloblastic Leukemia with Maturation, Leukemia, and Acute Myeloblastic Leukemia without Maturation. He is licensed to treat patients in Washington. Dr. Walter is currently accepting new patients.

View Profile
View All Doctors
What are the latest Acute Monoblastic Leukemia (AmoL) Clinical Trials?
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Recruiting
Start Date: October 26, 2020
Intervention Type: Drug
Study Drugs: Venetoclax, Decitabine, Azacitidine, Salsalate
Phase: Phase 2
View Trial
Summary: This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cance...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy
Status: Not yet recruiting
Start Date: June 2022
Intervention Type: Drug, Other
Study Drugs: Venetoclax, Azacitidine
Phase: Phase 2/Phase 3
View Trial
Summary: This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Acute Monoblastic Leukemia (AmoL)?
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Condition: Acute Myeloid Leukemia (AML)
Journal: Leukemia research
Treatment Used: Hypomethylating Agents (HMA)
Number of Patients: 0
Published: January 23, 2022
View publication
Summary: Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Chlovalicin B, a Chlorinated Sesquiterpene Isolated from the Marine Mushroom Digitatispora marina.
Journal: Molecules (Basel, Switzerland)
Published: December 24, 2021
View publication
Summary: Chlovalicin B, a Chlorinated Sesquiterpene Isolated from the Marine Mushroom Digitatispora marina.
Tired of the same old research?
Check Latest Advances
Biological Investigation of Amaryllidaceae Alkaloid Extracts from the Bulbs of Pancratium trianthum Collected in the Senegalese Flora.
Journal: Molecules (Basel, Switzerland)
Published: December 10, 2021
View publication
Summary: Biological Investigation of Amaryllidaceae Alkaloid Extracts from the Bulbs of Pancratium trianthum Collected in the Senegalese Flora.
View All Latest Advances